Articles

The route a drug takes into the body changes how much of it reaches the bloodstream, and how fast. Here we explain what bioavailability is, why the route matters, and what the evidence says about the idea that injections are always "stronger".

Biotin, hair complexes, plant extracts: every month a new bottle appears promising to stop hair loss. We look at what the evidence really says, what effect nutraceuticals have and why biotin can give you a scare on a blood test.

Alopecia areata is not the same as ordinary balding. We explain what defines it, why it happens, how it is diagnosed and how it differs from androgenetic alopecia, based on the evidence available today.

Vaginal dryness and pain during sex are common symptoms after the menopause and form part of what is known as genitourinary syndrome. We explain why it happens, what the evidence says and why effective treatment exists even though many women never seek help.

What testosterone therapy really is, who it is indicated for, how it is prescribed in Spain and what the evidence says about its benefits and its risks, without the hype or the anti-ageing promises.

Prediabetes is not an established disease, but a state of risk. We explain what the numbers mean, why it matters beyond blood sugar and what the evidence says about how to manage it.

For twenty years, a single study from 2002 frightened an entire generation of women and their doctors. We now know its findings were misread. Here's what menopausal hormone therapy really is, who it makes sense for and what its real risks are, with the figures on the table and the nuances that go with them.

Regaining some weight after stopping a GLP-1 receptor agonist is an expected physiological phenomenon, not a failure of willpower. We explain what the evidence from the semaglutide and tirzepatide trials shows, what comes back and what doesn't, and where things stand in Spain.

Low testosterone has become a catch-all explanation for tiredness or low mood, but genuine hypogonadism is something else: it requires specific symptoms plus a confirmed blood test, and it is less common than the marketing suggests. Here is what the evidence says, which symptoms really count, and why a single low reading diagnoses nothing.

Finasteride is one of the treatments authorised in Spain for androgenetic alopecia in men. We explain how it acts on DHT, what the trials show, which side effects the EMA has been monitoring since 2025 and why the decision is always an individual medical assessment.

Baricitinib (Olumiant) is the first systemic drug authorised in Spain for severe alopecia areata: in adults and in adolescents aged 12 and over, and publicly funded in adults. Here is what it is, what the trials found and where the caveats lie.

Perimenopause is the transition towards menopause, not a single point in time. We explain what it is, why it happens, how long it usually lasts and what the evidence says about the symptoms and their treatments, with nuance and without scaremongering.
Online medical assessment, prescription when appropriate and 1:1 follow-up with this team.